Status:
COMPLETED
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
Lead Sponsor:
AstraZeneca
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infe...
Detailed Description
This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infe...
Eligibility Criteria
Inclusion
- Immunocompromised patients who were administrated EVUSHELD as PrEP and have administration date of EVUSHELD
- patients aged ≥ 12 years at the index date
Exclusion
- Patients who have no medical visit records at any time in the 12 months preceding the index date
Key Trial Info
Start Date :
December 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 9 2024
Estimated Enrollment :
397 Patients enrolled
Trial Details
Trial ID
NCT06156982
Start Date
December 6 2023
End Date
January 9 2024
Last Update
June 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Osaka, Japan